Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma Exchange Therapy for Post-COVID-19 Condition
2022-000641-33Phase 2Completed
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-COVID syndrome comparing Therapeutic plasma exchange with Albutein 5% with Sham plasma exchange (placebo) (2 arms). Primary endpoint: Safety and tolerability (adverse events through day 90). Started Mar 2022; status: completed.
02
Drugs
albumin (human)
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on 2022-000641-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000641-33.